NewAmsterdam Pharma Company B.V.: NewAmsterdam Pharma Presen

- Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p - 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of - New Data Demonstrate

Related Keywords

Brooklyn , Florida , United States , Netherlands , Miami , Naarden , Noord Holland , Russia , Ukraine , Hannah Deresiewicz , Christiem Ballantyne , Matthew Philippe , Company Phase , Exchange Commission , Company Contact , Cardiovascular Research , Frazier Lifesciences Acquisition Corporation , National Lipid Association , Neither The Company , Newamsterdam Pharma Companynv Nasdaq , Baylor College Of Medicine , Menarini Group , Primary Endpoint , Median Reduction , Patients Treated , Ezetimibe Met Guideline Recommended , Data Demonstrate Statistically Significant , Clinically Meaningful Improvements , Additional Lipid , Lipoprotein Parameters Predictive , Cardiovascular Disease Risk , Tolerability Observed , Fixed Dose Combination Tablet Formula , Host Conference Call , Scientific Sessions , Consensus Decision Pathway , Baylor College , Full Data , Conference Call , Frazier Healthcare , Investor Relations , Newamsterdam , Dharma , Company , Presents , Bull , Data , Rom , Hase , Ose2 , Trial , Valuating , Bicetrapib , Combination , Ezetimibe , Adjunct , Thigh , Intensity , Statin , Therapy , Cientific , Sessions , 023 ,